Background: The revised version of Short-Form McGill Pain Questionnaire (SF-MPQ-2) has been developed as a tool for measuring both neuropathic and non-neuropathic pain which can be used in studies of epidemiology, pathophysiologic mechanisms, and treatment response. SF-MPQ-2 was expanded and revised from the Short-Form McGill Pain Questionnaire (SF-MPQ-1) pain descriptors by adding symptoms relevant to neuropathic pain and by modifying the response format to a 0 - 10 numerical rating scale. In this study, we translated the SF-MPQ-2 into Japanese. The aim of this study was the validation of a Japanese version of the SF-MPQ-2 in patients with neuropathic pain.
Materials and Methods: A total of 110 chronic pain patients from Osaka University Hospital and Nishinomiya Municipal Central Hospital were enrolled in this study, with 87 (47 males, 40 females) patients completing the study. Enrolled patients completed the SF-MPQ-2 which had been translated into Japanese. To evaluate the validity of the SF-MPQ-2 questionnaire, an exploratory factor analysis was performed. For assessment of reliability, we used internal consistency reliability coefficients (Cronbach's alpha coefficient) and the test-retest method test (Intraclass Correlation Coefficient; ICC) for the SF-MPQ-2 total and subscale scores. Validity was evaluated by examining the associations between the SF-MPQ-2 total and subscale scores and other measures.
Results: The internal consistency (Cronbach's alpha coefficient; continuous pain; α=0.883, intermittent pain; α=0.856, predominantly neuropathic pain; α=0.905, affective descriptors; α=0.863, total score; α=0.906) and reproducibility coefficient (ICC; continuous pain; ρ=0.793, intermittent pain; ρ=0.750, predominantly neuropathic pain; ρ=0.819, affective descriptors; ρ=0.760, total score; ρ=0.830) were high. There were significant correlations between SF-MPQ-2 and other functional assessments.
Conclusion: Our findings showed excellent reliability and validity for the Japanese version of the SF-MPQ-2 in pain patients, and the results of both exploratory and confirmatory factor analyses provided support for four readily interpretable subscales (continuous pain, intermittent pain, pre-dominantly neuropathic pain, and affective descriptors). These results provide a basis for use of the SF-MPQ-2 in future clinical research, including clinical trials of treatments for neuropathic and non-neuropathic pain conditions.